Frédéric Rolland
YOU?
Author Swipe
View article: MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer
MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer Open
Metronomic vinorelbine in combination with dual durvalumab plus tremelimumab immunotherapy had only moderate activity in pretreated advanced HNSCC.
View article: A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM) Open
The I2 substudy failed to demonstrate an activity of D + M in heavily pretreated patients with SCCHN previously exposed to anti-PD(L)1. No benefit was seen in PFS and OS.
View article: Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial Open
View article: Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO Open
Though the primary endpoint of OSAD93 was not met, this pre-operative doxorubicin-free regimen led to excellent long-term survival with limited toxicity in localized osteosarcoma.
View article: Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial Open
For the French translation of the abstract see Supplementary Materials section.
View article: PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort Open
These results reinforce clinical data on the expected benefit of ICI in metastatic pRCC treatment, as PD-L1 expression is a factor of poor prognosis in this multicenter cohort.
View article: Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study Open
Background: The extent of tumor shrinkage has been deemed a predictor of survival for advanced/metastatic renal cell carcinoma (RCC), a disease with historically poor survival. Objective: To perform an exploratory analysis of overall survi…
View article: PD-L1 Expression and its Prognostic Value in Metastatic Papillary Renal Cell Carcinoma: Results from a GETUG Multicenter Retrospective Cohort
PD-L1 Expression and its Prognostic Value in Metastatic Papillary Renal Cell Carcinoma: Results from a GETUG Multicenter Retrospective Cohort Open
View article: A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies Open
Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination…
View article: Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity Open
There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of afatinib, a pan-HER tyrosine kinase in…
View article: Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma Open
Background Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC, and associated with poor outcomes in the metastatic setting. In this study, we aimed to comprehensively evaluate the immune tumor microenvironment (TME…
View article: NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)
NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08) Open
Objective Salivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary gland CArcinoma of the…
View article: 935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM) Open
View article: 855MO Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)
855MO Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1) Open
View article: Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacy
Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacy Open
There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of afatinib, a pan-HER tyrosine kinase in…
View article: Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial
Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial Open
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Missense mutations in the polymerase epsilon (POLE) gene have been reported to generate proofreading defects resulting in an ultramutated genome and to sensitize tumors to checkpoint blockade immunotherapy. However, many POLE…
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Missense mutations in the polymerase epsilon (POLE) gene have been reported to generate proofreading defects resulting in an ultramutated genome and to sensitize tumors to checkpoint blockade immunotherapy. However, many POLE…
View article: Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS
Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS Open
Geriatric assessment (GA) can predict and improve treatment tolerance and estimate overall survival in older patients with cancer. Several international organizations promote GA; however, data related to its implementation in daily clinica…
View article: Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study Open
View article: Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial Open
We report long-term efficacy and overall survival (OS) results from a randomised, double-blind, phase 2 study (NCT02022098) investigating xevinapant plus standard-of-care chemoradiotherapy (CRT) vs. placebo plus CRT in 96 patients with unr…
View article: Gemcitabine Plus Platinum-Based Chemotherapy in Combination with Bevacizumab for Kidney Metastatic Collecting Duct and Medullary Carcinomas: Results of a Prospective Phase II Trial (BEVABEL- GETUG/AFU24)
Gemcitabine Plus Platinum-Based Chemotherapy in Combination with Bevacizumab for Kidney Metastatic Collecting Duct and Medullary Carcinomas: Results of a Prospective Phase II Trial (BEVABEL- GETUG/AFU24) Open